康芝药业：止咳橘红颗粒获临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its product "Cough Orange Granules," which is already in production and sales [1] Group 1: Product Information - "Cough Orange Granules" is a national secondary protected traditional Chinese medicine with functions for "clearing the lungs, stopping cough, and resolving phlegm" [1] - The product is indicated for cough with phlegm due to phlegm-heat obstructing the lungs, characterized by symptoms such as excessive phlegm, chest fullness, shortness of breath, dry throat, and itching [1] Group 2: Clinical Trial Approval - The company submitted an application to add a new indication for "acute exacerbation of chronic obstructive pulmonary disease (phlegm-heat obstructing the lungs)" and received approval for clinical trials [1] - This approval represents a milestone in the company's drug development efforts [1] Group 3: Financial Impact - The approval of the clinical trial does not have a significant impact on the company's short-term financial status or operating performance [1] - The sales of the product will not be affected by the receipt of the clinical trial approval notification [1]